AsymBio’s Post

Molecule One-Pager: ARV-471 (vepdegestrant) | https://lnkd.in/g7ykPxc9 Arvinas’ ARV-471 is an orally bioavailable CRBN-based ER PROTAC degrader for treating patients with ER+/HER2-breast cancer and the first PROTAC to enter Ph. III clinical trials. For a long time, the scientific community was skeptical that PROTACs could be suitable for once-daily oral dosing, and molecules like ARV-471 have ended that dogma. This molecule one-pager serves as a reference guide, offering an overview of the scientific significance of Arvinas' ARV-471 program. It includes links to key presentations, publications, patents, preclinical and clinical PK data summaries, and more. Check out the one-pager for ARV-471: https://lnkd.in/g7ykPxc9

Did you know that there are nearly 61,000 new cancer cases per year in the US that harbor RASG12D mutations?[1] If you have a RAS-targeting drug development strategy, you’ll want to access our 56 unique PDX cancer models and companion PDX-derived 3D cell culture models with the most common RAS activations for preclinical validation. Download the data pack now: https://hubs.la/Q02vZSW60. #KRAS #RAS #TargetedTherapies #DrugDevelopment #CancerResearch #AACR24 [1] New Drugs on the Horizon: Part 1, AACR 2024 Annual Meeting; April 7.

Marc-Henry PITTY, MD, CEO of Oregon Therapeutics, "To date, our first-in-class #metabolicinhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple #cancer types. Lantern’s (NASDAQ: LTRN) #RADR®AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and #biomarker signatures that can aid in the design of future #clinicaltrials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions." https://lnkd.in/gabi_27S #biotech #france #texas #oncology #artificialIntelligence

This piece by Ned Pagliarulo in BioPharma Dive is a great primer on our recently announced collaboration with ARTBIO and the excitement surrounding #radiopharmaceuticals overall. As Ned writes, “The radiopharma field is booming, drawing substantial investment from large companies and venture capital firms eager to capitalize on the drugs’ potential to balance cancer-killing potency with better safety.” The Helicon-enabled radioligand therapies we will co-develop will benefit from the hyper-tunability of Helicons, to control the drugs’ distribution and half-life, and from the uniqueness of lead-212, one of the most promising isotopes for radiopharmaceutical use. Check out this photo of our teams together kicking off our partnership, and read the story here: https://bit.ly/3KN2zm5 #radioligandtherapy #cancer #oncology #peptides #Helicons #patients  

Congratulations, Mestag Therapeutics! The Cambridge-based biotech shared in a £12 million Innovate UK grant to advance nextgen immunotherapies for cancer, securing £1.5m of the total UK allocation. Harnessing new insights into fibroblast-immune interactions, Mestag is using the award to accelerate the development of its MST-0300 antibody. MST-0300 is a first-in-class bispecific antibody designed to induce TLS in solid tumours in a highly specific and localised fashion. The presence of TLS in tumours has recently emerged as being strongly correlated with improved outcomes for cancer patients across multiple tumour types. #mabs https://lnkd.in/dTBkp-7C

Translational Drug Development (TD2) understands the Preclinical, Bioanalytical, Regulatory, and Clinical challenges of ADC development and knows how to approach those challenges to provide an efficient path from "Bench to Bedside". Working in the ADC realm? Need a CRO partner? Let's discuss the TD2 difference! #adc #antibodydrugconjugate #preclinical #bioanalytical #clinicaltrial #regulatoryconsulting #adcdevelopment #td2 #translationaldrugdevelopment #td2difference #benchtobedside

🎖Check out the Highly cited #Review "Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer" 👋by Briana Kinnel (Morehouse School of Medicine) et al. 📌Access the full paper here: https://lnkd.in/dPab5v5R Keywords: drug resistance; MDR; HER2; iNOS; aryl hydrocarbon receptor; PTK6; CDK4/6; Wnt/β-catenin

Marc-Henry PITTY, MD, CEO of Oregon Therapeutics, "To date, our first-in-class #metabolicinhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple #cancer types. Lantern’s (NASDAQ: LTRN) #RADR®AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and #biomarker signatures that can aid in the design of future #clinicaltrials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions." https://lnkd.in/g8XPQSsa #biotech #france #texas #oncology #artificialIntelligence

At Pfizer, we are advancing a deep and diverse pipeline that spans three core scientific modalities to attack cancer from multiple angles, including more than 25 new molecular entities. Today at #ASCO24, we are excited to share updated Phase 1 data for several of our priority pipeline therapies, including an oral presentation on our promising investigational integrin beta-6-directed ADC in #NSCLC, which initiated a Phase 3 trial this year. We’re also sharing updated results for our potential first-in-class KAT6 inhibitor in ER+, HER2- metastatic #breastcancer, which were also published in Nature Medicine. Read more here: https://lnkd.in/gA9Y3QA6

In last 14 days, USPTO granted a patent (US20250000991A1) on antibody drug conjugates (ADCs) targeting Nectin-4. The drug payload is a camptothecin analog. Nectin-4 is a member of part of the nectin family of calcium-independent immunoglobulin-like adhesion molecules, the overexpression of which has been observed in several cancer types. Two other ADCs on this target are enfortumab vedotin (Astellas Pharma, approved, MMAE payload) and bulumtatug fuvedotin (Mabwell, Ph3 NCT06692166, MMAE payload). The inventors of this patent are Jeffrey Boyles, Kyla Driscoll, Omar Duramad, Qianxu Guo, Rikke Bæk Holmgaard, Kevin Lindquist, Joshua Park, Divya Sagar, Mohan Srinivasan, Petra Verdino, Jieyu Zhou from Eli Lilly and Company. We look forward to further promising clinical results on these novel ADCs. #ADC #antibody #Nectin4 #cancer